Samsung Biologics to buy US drug production facility from GSK for $280 million

SEOUL: South Korea’s Samsung Biologics said ⁠on Monday it is acquiring its first U.S. drug production facility from GSK for $280 million to respond ‌to long-term ‌U.S. market demand.

The company’s U.S. unit, Samsung Biologics ‌America, is acquiring a 100% stake in Human Genome Sciences Inc of Rockville, Maryland, the South Korean contract drug manufacturer said in a statement.

Samsung Biologics plans additional investments to expand the site’s capacity, currently a ‌combined 60,000 ‍liters of drug substance capacity, and ‍to upgrade technology, it said.